...
首页> 外文期刊>BMJ Open >Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval
【24h】

Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval

机译:患有骨转移的乳腺癌患者的生存:一项基于丹麦人群的队列研究,研究了疾病初始阶段对乳腺癌诊断的预后影响以及无骨转移间隔的时间

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objectives Since population-based data on prognostic factors affecting survival in patients with breast cancer with bone metastasis (BM) are currently limited, we conducted this nationwide retrospective cohort study to examine the prognostic role of disease stage at breast cancer diagnosis and length of BM-free interval (BMFI). Setting Denmark. Participants 2427 women with a breast cancer diagnosis between 1997 and 2011 in the Danish Cancer Registry and a concurrent or subsequent BM diagnosis in the Danish National Registry of Patients. Primary and secondary outcome measures Survival (crude) based on Kaplan-Meier method and mortality risk (crude and adjusted for age, year of diagnosis, estrogen receptor status and comorbidity) based on Cox proportional hazards regression analyses by stage of disease at breast cancer diagnosis and by length of BMFI (time from breast cancer to BM diagnosis), following patients from BM diagnosis until death, emigration or until 31 December 2012, whichever came first. Results Survival decreased with more advanced stage of disease at the time of breast cancer diagnosis; risk of mortality during the first year following a BM diagnosis was over two times higher for those presenting with metastatic versus localised disease (adjusted HR=2.12 (95% CI 1.71 to 2.62)). With respect to length of BMFI, survival was highest in women with a BMFI 1?year (ie, in those who presented with BM at the time of breast cancer diagnosis or were diagnosed within 1?year). However, among patients with a BMFI ≥1?year, survival increased with longer BMFI (1-year survival: 39.9% (95% CI 36.3% to 43.6%) for BMFI 1 to 3?years and 52.6% (95% CI 47.4% to 57.6%) for BMFI ≥5?years). This pattern was also observed in multivariate analyses. Conclusions Stage of disease at breast cancer diagnosis and length of BMFI appear to be important prognostic factors for survival following BM.
机译:目的由于基于人群的影响骨转移癌(BM)患者生存的预后因素的数据目前有限,因此我们进行了这项全国性的回顾性队列研究,以检查疾病阶段在乳腺癌诊断中的预后作用以及BM-空闲间隔(BMFI)。设置丹麦。参与者2427名在1997年至2011年之间在丹麦癌症登记处被诊断出患有乳腺癌,并在丹麦国家患者登记簿中被诊断为并发或随后进行BM的女性。主要和次要结局指标基于Kaplan-Meier方法的生存率(粗略)和基于乳腺癌诊断阶段的Cox比例风险回归分析得出的死亡率风险(粗略和调整年龄,诊断年份,雌激素受体状态和合并症)从BM诊断到死亡,移民或直到2012年12月31日(以先到者为准)的BMFI长度(从乳腺癌到BM诊断的时间)。结果在乳腺癌诊断时,随着疾病的晚期发展,生存率降低;对于那些患有转移性疾病与局部性疾病的患者,BM诊断后第一年的死亡风险要高出两倍以上(校正后的HR = 2.12(95%CI为1.71至2.62))。就BMFI的长度而言,BMFI <1?年的妇女(即,那些在乳腺癌诊断时出现BM或在1年内被确诊的妇女)的生存率最高。然而,在BMFI≥1年的患者中,BMFI更长(1年生存率:39.9%(95%CI 36.3%至43.6%)的BMFI 1年和3.6%和52.6%(95%CI)的患者生存率提高了。对于BMFI≥5年,则为47.4%至57.6%)。在多变量分析中也观察到了这种模式。结论乳腺癌诊断的疾病阶段和BMFI的长度似乎是BM生存的重要预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号